Claus Hanusch

14.0k total citations · 2 hit papers
81 papers, 4.3k citations indexed

About

Claus Hanusch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claus Hanusch has authored 81 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 63 papers in Cancer Research and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claus Hanusch's work include Breast Cancer Treatment Studies (53 papers), Cancer Treatment and Pharmacology (32 papers) and HER2/EGFR in Cancer Research (26 papers). Claus Hanusch is often cited by papers focused on Breast Cancer Treatment Studies (53 papers), Cancer Treatment and Pharmacology (32 papers) and HER2/EGFR in Cancer Research (26 papers). Claus Hanusch collaborates with scholars based in Germany, Switzerland and United States. Claus Hanusch's co-authors include Sibylle Loibl, Gϋnter von Minckwitz, Carsten Denkert, Christian Jackisch, Jens Huober, Jens‐Uwe Blohmer, Michael Untch, Holger Eidtmann, Christine Solbach and J. Hilfrich and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Claus Hanusch

81 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

2009 1.3k citations Carsten Denkert, Sibylle Loibl et al. Journal of Clinical Oncology profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claus Hanusch Germany	27	3.3k	2.2k	741	640	622	81	4.3k
Maria Vittoria Dieci Italy	36	3.1k 0.9×	1.6k 0.7×	750 1.0×	310 0.5×	642 1.0×	154	4.5k
Yeon Hee Park South Korea	34	2.5k 0.7×	1.5k 0.7×	410 0.6×	366 0.6×	486 0.8×	196	4.1k
Debora Fumagalli Belgium	24	2.2k 0.7×	1.2k 0.6×	559 0.8×	478 0.7×	279 0.4×	83	3.3k
Peter Savas Australia	23	3.2k 1.0×	1.1k 0.5×	1.7k 2.3×	286 0.4×	357 0.6×	49	4.3k
David N. Church United Kingdom	28	1.7k 0.5×	1.3k 0.6×	458 0.6×	1.2k 1.9×	358 0.6×	75	4.4k
Atilla Ömeroğlu Canada	23	1.6k 0.5×	1.9k 0.9×	407 0.5×	779 1.2×	306 0.5×	74	4.0k
Filippo Montemurro Italy	36	2.8k 0.8×	1.1k 0.5×	227 0.3×	472 0.7×	1.5k 2.4×	180	4.4k
Yoon‐La Choi South Korea	35	1.6k 0.5×	1.1k 0.5×	342 0.5×	352 0.6×	426 0.7×	125	3.7k
Ashley Cimino‐Mathews United States	37	2.2k 0.7×	922 0.4×	784 1.1×	655 1.0×	166 0.3×	122	3.8k
Elisabetta Munzone Italy	31	2.4k 0.7×	1.4k 0.6×	172 0.2×	251 0.4×	302 0.5×	129	3.3k

Countries citing papers authored by Claus Hanusch

Since Specialization

Citations

This map shows the geographic impact of Claus Hanusch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Hanusch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Hanusch more than expected).

Fields of papers citing papers by Claus Hanusch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus Hanusch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Hanusch. The network helps show where Claus Hanusch may publish in the future.

Co-authorship network of co-authors of Claus Hanusch

This figure shows the co-authorship network connecting the top 25 collaborators of Claus Hanusch. A scholar is included among the top collaborators of Claus Hanusch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus Hanusch. Claus Hanusch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loibl, S., Michael Untch, Jens Huober, et al.. (2025). 292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial. Annals of Oncology. 36. S303–S304. 1 indexed citations

Huebner, Hanna, Matthias Rübner, Andreas Schneeweiß, et al.. (2023). RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.. Journal of Clinical Oncology. 41(16_suppl). 1011–1011. 1 indexed citations

Denkert, Carsten, Andreas Schneeweiß, Julia Rey, et al.. (2022). Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.. Journal of Clinical Oncology. 40(16_suppl). 583–583. 4 indexed citations

Loibl, Sibylle, Andreas Schneeweiß, Jens Huober, et al.. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of Oncology. 33(11). 1149–1158. 136 indexed citations breakdown →

Reinisch, Mattea, Jens‐Uwe Blohmer, Theresa Link, et al.. (2022). 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Annals of Oncology. 33. S166–S167. 1 indexed citations

Braun, Michael, Monika Kriner, Claus Hanusch, et al.. (2021). Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level. Breast Care. 17(3). 288–295. 2 indexed citations

Link, Theresa, Jens‐Uwe Blohmer, Marianne Just, et al.. (2020). 168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Annals of Oncology. 31. S308–S309. 2 indexed citations

Huober, Jens, Andreas Schneeweiß, Jens‐Uwe Blohmer, et al.. (2019). Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database. Annals of Oncology. 30. iii34–iii34. 4 indexed citations

Loibl, Sibylle, Bruno V. Sinn, Thomas Karn, et al.. (2019). Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.. Journal of Clinical Oncology. 37(15_suppl). 509–509. 8 indexed citations

10.

Untch, Michael, Gϋnter von Minckwitz, Bernd Gerber, et al.. (2018). Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology. 36(13). 1308–1316. 40 indexed citations

11.

Mackelenbergh, Marion van, Carsten Denkert, Valentina Nekljudova, et al.. (2017). Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment. 167(1). 59–71. 34 indexed citations

12.

Kümmel, Sherko, Stefan Paepke, Jens Huober, et al.. (2017). Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European Journal of Cancer. 84. 1–8. 17 indexed citations

13.

Loibl, Sibylle, Christian Jackisch, Bianca Lederer, et al.. (2015). Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Research and Treatment. 152(2). 377–387. 77 indexed citations

14.

Minckwitz, Gϋnter von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2013). Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology. 31(29). 3623–3630. 265 indexed citations

15.

Minckwitz, Gϋnter von, Mahdi Rezai, Peter A. Fasching, et al.. (2013). Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro). Annals of Oncology. 25(1). 81–89. 51 indexed citations

16.

Untch, Michael, Sibylle Loibl, Joachim Bischoff, et al.. (2012). Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. The Lancet Oncology. 13(2). 135–144. 297 indexed citations

17.

Minckwitz, Gϋnter von, Silvia Darb‐Esfahani, Sibylle Loibl, et al.. (2011). Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40). Breast Cancer Research and Treatment. 132(3). 863–870. 35 indexed citations

18.

Minckwitz, G von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2011). S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial.. Cancer Research. 71(24_Supplement). S3–2. 28 indexed citations

19.

Witzel, Isabell, Sibylle Loibl, G von Minckwitz, et al.. (2010). Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Research and Treatment. 123(2). 437–445. 37 indexed citations

20.

Minckwitz, Gϋnter von, Sherko Kümmel, Claus Hanusch, et al.. (2008). Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study. JNCI Journal of the National Cancer Institute. 100(8). 552–562. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact